The case for & against
Bull & Bear analysis
Bearish
Eiger BioPharmaceuticals, Inc. (EIGR) was a biotechnology company focused on developing therapies for rare and ultra-rare diseases. Prior to its bankruptcy, Eiger's pipeline included notable products aimed at treating hepatitis delta virus (HDV) infection, progeria, and congenital hyperinsulinism. The company also marketed Zokinvy, an approved therapy for progeria and aimed to address significant unmet medical needs in rare diseases. However, with the recent announcement of Chapter 11 bankruptcy, the company's operations have ceased, and its stock is no longer trading on major exchanges.
Bull says
- ↑Focus on orphan markets: progeria, HDV, congenital hyperinsulinism
- ↑Zokinvy approved for progeria; Lonafarnib, Peginterferon Lambda in pipeline
- ↑Orphan-drug pricing power could drive high margins
- ↑Potential acquiror interest from larger pharma to expand rare-disease portfolios
- ↑High earnings yield and strong momentum factors signaled past investor confidence
- ↑Attracted significant market interest during clinical progress phases
Bear says
- ↓Chapter 11 bankruptcy filed April 2024; operations fully ceased
- ↓Delisted from NASDAQ; stock trading halted indefinitely
- ↓Total shareholder value lost; no recovery prospects post-bankruptcy
- ↓Failed to commercialize therapies; pipeline assets unproven
- ↓Elevated cash burn and negative cash flows; leverage risk high
- ↓Absence of positive factor signals implies heightened downside risk